Given that NKG2DLs are extensively expressed on non-T cells, such as monocytes and glomeruli, in SLE or lupus nephritis16, 24, NKG2D antibody therapy would also be expected to block the mutual activation of these cells with NKG2D+CD4+ T cells. Here, KLRK1 is linked to systemic lupus erythematosus.